Literature DB >> 31770050

Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Jennifer R Shingleton1, Sandeep S Dave1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31770050     DOI： 10.1200/JCO.19.02587

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  1 in total

1.  [Efficacy and safety of Polatuzumab Vedotin in combination with rituximab plus bendamustine in patients with relapsed/refractory diffuse large B-cell lymphoma: a single center analysis].

Authors:  F C Kong; M Yu; Y L Zhou; S X Wang; F Li
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-01-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.